NovoCure Ltd (NVCR) stock
NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$11.14−0.16 (-1.42%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
NovoCure r&d expenses
Research and development expenses are spending on new products and technology.
NovoCure's R&D Expenses for the twelve months ending Sep 30, 2026 was $228.79M, up 6.5% year over year. For fiscal 2025 it was $224.54M, up 7.1% from the year before. Over ten years it grew 17.8% a year on average. The highest annual figure on record is $224.54M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $224.54M | +7.1% |
| FY2024 | Dec 31, 2024 | $209.65M | -6.0% |
| FY2023 | Dec 31, 2023 | $223.06M | +8.2% |
| FY2022 | Dec 31, 2022 | $206.09M | +2.4% |
| FY2021 | Dec 31, 2021 | $201.30M | +52.5% |
| FY2020 | Dec 31, 2020 | $132.01M | +67.1% |
| FY2019 | Dec 31, 2019 | $79.00M | +56.2% |
| FY2018 | Dec 31, 2018 | $50.57M | +32.7% |
| FY2017 | Dec 31, 2017 | $38.10M | -8.1% |
| FY2016 | Dec 31, 2016 | $41.47M | -5.2% |
| FY2015 | Dec 31, 2015 | $43.75M | +8.3% |
| FY2014 | Dec 31, 2014 | $40.38M | +16.0% |
| FY2013 | Dec 31, 2013 | $34.80M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $58.10M | +7.5% |
| Q2 FY2026 | Jun 30, 2026 | $51.45M | -7.9% |
| Q1 FY2026 | Mar 31, 2026 | $58.34M | +8.5% |
| Q4 FY2025 | Dec 31, 2025 | $60.91M | +18.9% |
| Q3 FY2025 | Sep 30, 2025 | $54.03M | +4.1% |
| Q2 FY2025 | Jun 30, 2025 | $55.83M | +1.6% |
| Q1 FY2025 | Mar 31, 2025 | $53.78M | +4.2% |
| Q4 FY2024 | Dec 31, 2024 | $51.21M | -5.7% |
| Q3 FY2024 | Sep 30, 2024 | $51.88M | -3.2% |
| Q2 FY2024 | Jun 30, 2024 | $54.96M | -0.9% |
| Q1 FY2024 | Mar 31, 2024 | $51.60M | -13.6% |
| Q4 FY2023 | Dec 31, 2023 | $54.31M | -0.9% |
| Q3 FY2023 | Sep 30, 2023 | $53.62M | +3.2% |
| Q2 FY2023 | Jun 30, 2023 | $55.43M | -2.9% |
| Q1 FY2023 | Mar 31, 2023 | $59.70M | +41.4% |
| Q4 FY2022 | Dec 31, 2022 | $54.82M | -3.7% |
| Q3 FY2022 | Sep 30, 2022 | $51.96M | +7.9% |
| Q2 FY2022 | Jun 30, 2022 | $57.08M | +13.4% |
| Q1 FY2022 | Mar 31, 2022 | $42.23M | -8.0% |
| Q4 FY2021 | Dec 31, 2021 | $56.93M | +29.4% |
| Q3 FY2021 | Sep 30, 2021 | $48.14M | +46.7% |
| Q2 FY2021 | Jun 30, 2021 | $50.32M | +68.2% |
| Q1 FY2021 | Mar 31, 2021 | $45.92M | +81.7% |
| Q4 FY2020 | Dec 31, 2020 | $44.00M | +85.3% |
| Q3 FY2020 | Sep 30, 2020 | $32.82M | +74.9% |
| Q2 FY2020 | Jun 30, 2020 | $29.92M | +53.8% |
| Q1 FY2020 | Mar 31, 2020 | $25.27M | +48.3% |
| Q4 FY2019 | Dec 31, 2019 | $23.74M | +57.9% |
| Q3 FY2019 | Sep 30, 2019 | $18.77M | +43.5% |
| Q2 FY2019 | Jun 30, 2019 | $19.45M | +71.2% |
| Q1 FY2019 | Mar 31, 2019 | $17.04M | +53.5% |
| Q4 FY2018 | Dec 31, 2018 | $15.03M | +49.6% |
| Q3 FY2018 | Sep 30, 2018 | $13.07M | +41.0% |
| Q2 FY2018 | Jun 30, 2018 | $11.36M | +21.2% |
| Q1 FY2018 | Mar 31, 2018 | $11.10M | +18.0% |
| Q4 FY2017 | Dec 31, 2017 | $10.05M | +18.6% |
| Q3 FY2017 | Sep 30, 2017 | $9.27M | – |
| Q2 FY2017 | Jun 30, 2017 | $9.37M | – |
| Q1 FY2017 | Mar 31, 2017 | $9.41M | – |
| Q4 FY2016 | Dec 31, 2016 | $8.47M | – |
See a number that looks wrong?